MedTrace Logo

Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women

NCT00697463 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-07-26

Study results available
· View outcomes & findings →

Summary

Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young individuals sustain one or more low-trauma fractures. Teriparatide \[PTH(1-34)\], which is FDA approved for treatment of osteoporosis in men and postmenopausal women, works by stimulating bone formation. The investigators hypothesize that teriparatide will significantly increase bone density (BMD) and improve bone structure in premenopausal women with IOP.

Conditions

Interventions

DRUG

Teriparatide (PTH 1-34)

20 micrograms subcutaneous injection daily

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Shane, MD · Columbia University

  • Adi Cohen, MD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-20
Primary Completion
2012-01-03
Completion
2012-01-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00697463 on ClinicalTrials.gov